Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients
The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP)). Unfortunately, chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse...
Saved in:
| Published in | BMC cancer Vol. 21; no. 1; p. 1319 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
09.12.2021
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP)). Unfortunately, chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event of these two regimens. The efficacy of pregabalin for CIPN has been reported in previous studies. However, the efficacy of mirogabalin for CIPN remains unknown. Thus, in this study, we aimed to clarify which drug (mirogabalin or pregabalin) was more valuable for improving CIPN.
A total of 163 PC patients who underwent FOLFIRINOX or GnP between May 2014 and January 2021 were enrolled. Among them, 34 patients were diagnosed with CIPN. Thirteen patients were treated with mirogabalin (mirogabalin group), and twenty-one patients were treated with pregabalin (pregabalin group). Treatment efficacy was compared between the two groups.
In both the mirogabalin group and the pregabalin group, the grade of patients with CIPN at 2, 4, and 6 weeks after the initiation of treatment showed significant improvement compared to the pretreatment grade. Notably, the rate of CIPN improvement was higher in the mirogabalin group than in the pregabalin group (2 weeks: 84.6% (11/13) vs 33.3% (7/21), P value = 0.005; 4 weeks, 6 weeks: 92.3% (12/13) vs 33.3% (7/21), P value = 0.001).
Although both mirogabalin and pregabalin were effective at improving CIPN, mirogabalin might be a suitable first choice for CIPN in PC patients.
Not applicable. |
|---|---|
| AbstractList | The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP)). Unfortunately, chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event of these two regimens. The efficacy of pregabalin for CIPN has been reported in previous studies. However, the efficacy of mirogabalin for CIPN remains unknown. Thus, in this study, we aimed to clarify which drug (mirogabalin or pregabalin) was more valuable for improving CIPN.
A total of 163 PC patients who underwent FOLFIRINOX or GnP between May 2014 and January 2021 were enrolled. Among them, 34 patients were diagnosed with CIPN. Thirteen patients were treated with mirogabalin (mirogabalin group), and twenty-one patients were treated with pregabalin (pregabalin group). Treatment efficacy was compared between the two groups.
In both the mirogabalin group and the pregabalin group, the grade of patients with CIPN at 2, 4, and 6 weeks after the initiation of treatment showed significant improvement compared to the pretreatment grade. Notably, the rate of CIPN improvement was higher in the mirogabalin group than in the pregabalin group (2 weeks: 84.6% (11/13) vs 33.3% (7/21), P value = 0.005; 4 weeks, 6 weeks: 92.3% (12/13) vs 33.3% (7/21), P value = 0.001).
Although both mirogabalin and pregabalin were effective at improving CIPN, mirogabalin might be a suitable first choice for CIPN in PC patients.
Not applicable. The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP)). Unfortunately, chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event of these two regimens. The efficacy of pregabalin for CIPN has been reported in previous studies. However, the efficacy of mirogabalin for CIPN remains unknown. Thus, in this study, we aimed to clarify which drug (mirogabalin or pregabalin) was more valuable for improving CIPN. A total of 163 PC patients who underwent FOLFIRINOX or GnP between May 2014 and January 2021 were enrolled. Among them, 34 patients were diagnosed with CIPN. Thirteen patients were treated with mirogabalin (mirogabalin group), and twenty-one patients were treated with pregabalin (pregabalin group). Treatment efficacy was compared between the two groups. In both the mirogabalin group and the pregabalin group, the grade of patients with CIPN at 2, 4, and 6 weeks after the initiation of treatment showed significant improvement compared to the pretreatment grade. Notably, the rate of CIPN improvement was higher in the mirogabalin group than in the pregabalin group (2 weeks: 84.6% (11/13) vs 33.3% (7/21), P value = 0.005; 4 weeks, 6 weeks: 92.3% (12/13) vs 33.3% (7/21), P value = 0.001). Although both mirogabalin and pregabalin were effective at improving CIPN, mirogabalin might be a suitable first choice for CIPN in PC patients. Abstract Background The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP)). Unfortunately, chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event of these two regimens. The efficacy of pregabalin for CIPN has been reported in previous studies. However, the efficacy of mirogabalin for CIPN remains unknown. Thus, in this study, we aimed to clarify which drug (mirogabalin or pregabalin) was more valuable for improving CIPN. Methods A total of 163 PC patients who underwent FOLFIRINOX or GnP between May 2014 and January 2021 were enrolled. Among them, 34 patients were diagnosed with CIPN. Thirteen patients were treated with mirogabalin (mirogabalin group), and twenty-one patients were treated with pregabalin (pregabalin group). Treatment efficacy was compared between the two groups. Results In both the mirogabalin group and the pregabalin group, the grade of patients with CIPN at 2, 4, and 6 weeks after the initiation of treatment showed significant improvement compared to the pretreatment grade. Notably, the rate of CIPN improvement was higher in the mirogabalin group than in the pregabalin group (2 weeks: 84.6% (11/13) vs 33.3% (7/21), P value = 0.005; 4 weeks, 6 weeks: 92.3% (12/13) vs 33.3% (7/21), P value = 0.001). Conclusions Although both mirogabalin and pregabalin were effective at improving CIPN, mirogabalin might be a suitable first choice for CIPN in PC patients. Trial registration Not applicable Background The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP)). Unfortunately, chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event of these two regimens. The efficacy of pregabalin for CIPN has been reported in previous studies. However, the efficacy of mirogabalin for CIPN remains unknown. Thus, in this study, we aimed to clarify which drug (mirogabalin or pregabalin) was more valuable for improving CIPN. Methods A total of 163 PC patients who underwent FOLFIRINOX or GnP between May 2014 and January 2021 were enrolled. Among them, 34 patients were diagnosed with CIPN. Thirteen patients were treated with mirogabalin (mirogabalin group), and twenty-one patients were treated with pregabalin (pregabalin group). Treatment efficacy was compared between the two groups. Results In both the mirogabalin group and the pregabalin group, the grade of patients with CIPN at 2, 4, and 6 weeks after the initiation of treatment showed significant improvement compared to the pretreatment grade. Notably, the rate of CIPN improvement was higher in the mirogabalin group than in the pregabalin group (2 weeks: 84.6% (11/13) vs 33.3% (7/21), P value = 0.005; 4 weeks, 6 weeks: 92.3% (12/13) vs 33.3% (7/21), P value = 0.001). Conclusions Although both mirogabalin and pregabalin were effective at improving CIPN, mirogabalin might be a suitable first choice for CIPN in PC patients. Trial registration Not applicable Keywords: chemotherapy-induced peripheral neuropathy, mirogabalin, pregabalin, pancreatic cancer Background The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP)). Unfortunately, chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event of these two regimens. The efficacy of pregabalin for CIPN has been reported in previous studies. However, the efficacy of mirogabalin for CIPN remains unknown. Thus, in this study, we aimed to clarify which drug (mirogabalin or pregabalin) was more valuable for improving CIPN. Methods A total of 163 PC patients who underwent FOLFIRINOX or GnP between May 2014 and January 2021 were enrolled. Among them, 34 patients were diagnosed with CIPN. Thirteen patients were treated with mirogabalin (mirogabalin group), and twenty-one patients were treated with pregabalin (pregabalin group). Treatment efficacy was compared between the two groups. Results In both the mirogabalin group and the pregabalin group, the grade of patients with CIPN at 2, 4, and 6 weeks after the initiation of treatment showed significant improvement compared to the pretreatment grade. Notably, the rate of CIPN improvement was higher in the mirogabalin group than in the pregabalin group (2 weeks: 84.6% (11/13) vs 33.3% (7/21), P value = 0.005; 4 weeks, 6 weeks: 92.3% (12/13) vs 33.3% (7/21), P value = 0.001). Conclusions Although both mirogabalin and pregabalin were effective at improving CIPN, mirogabalin might be a suitable first choice for CIPN in PC patients. Trial registration Not applicable Abstract Background The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP)). Unfortunately, chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event of these two regimens. The efficacy of pregabalin for CIPN has been reported in previous studies. However, the efficacy of mirogabalin for CIPN remains unknown. Thus, in this study, we aimed to clarify which drug (mirogabalin or pregabalin) was more valuable for improving CIPN. Methods A total of 163 PC patients who underwent FOLFIRINOX or GnP between May 2014 and January 2021 were enrolled. Among them, 34 patients were diagnosed with CIPN. Thirteen patients were treated with mirogabalin (mirogabalin group), and twenty-one patients were treated with pregabalin (pregabalin group). Treatment efficacy was compared between the two groups. Results In both the mirogabalin group and the pregabalin group, the grade of patients with CIPN at 2, 4, and 6 weeks after the initiation of treatment showed significant improvement compared to the pretreatment grade. Notably, the rate of CIPN improvement was higher in the mirogabalin group than in the pregabalin group (2 weeks: 84.6% (11/13) vs 33.3% (7/21), P value = 0.005; 4 weeks, 6 weeks: 92.3% (12/13) vs 33.3% (7/21), P value = 0.001). Conclusions Although both mirogabalin and pregabalin were effective at improving CIPN, mirogabalin might be a suitable first choice for CIPN in PC patients. Trial registration Not applicable BACKGROUNDThe prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP)). Unfortunately, chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event of these two regimens. The efficacy of pregabalin for CIPN has been reported in previous studies. However, the efficacy of mirogabalin for CIPN remains unknown. Thus, in this study, we aimed to clarify which drug (mirogabalin or pregabalin) was more valuable for improving CIPN. METHODSA total of 163 PC patients who underwent FOLFIRINOX or GnP between May 2014 and January 2021 were enrolled. Among them, 34 patients were diagnosed with CIPN. Thirteen patients were treated with mirogabalin (mirogabalin group), and twenty-one patients were treated with pregabalin (pregabalin group). Treatment efficacy was compared between the two groups. RESULTSIn both the mirogabalin group and the pregabalin group, the grade of patients with CIPN at 2, 4, and 6 weeks after the initiation of treatment showed significant improvement compared to the pretreatment grade. Notably, the rate of CIPN improvement was higher in the mirogabalin group than in the pregabalin group (2 weeks: 84.6% (11/13) vs 33.3% (7/21), P value = 0.005; 4 weeks, 6 weeks: 92.3% (12/13) vs 33.3% (7/21), P value = 0.001). CONCLUSIONSAlthough both mirogabalin and pregabalin were effective at improving CIPN, mirogabalin might be a suitable first choice for CIPN in PC patients. TRIAL REGISTRATIONNot applicable. |
| ArticleNumber | 1319 |
| Audience | Academic |
| Author | Irie, Hiroki Takasumi, Mika Suzuki, Rei Konno, Naoki Kato, Tsunetaka Kobashi, Ryoichiro Hikichi, Takuto Sato, Yuki Ohira, Hiromasa Okubo, Yoshinori Nakamura, Jun Hashimoto, Minami Asama, Hiroyuki Sugimoto, Mitsuru Takagi, Tadayuki |
| Author_xml | – sequence: 1 givenname: Mitsuru surname: Sugimoto fullname: Sugimoto, Mitsuru email: kita335@fmu.ac.jp organization: Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan. kita335@fmu.ac.jp – sequence: 2 givenname: Tadayuki surname: Takagi fullname: Takagi, Tadayuki organization: Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan – sequence: 3 givenname: Rei surname: Suzuki fullname: Suzuki, Rei organization: Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan – sequence: 4 givenname: Naoki surname: Konno fullname: Konno, Naoki organization: Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan – sequence: 5 givenname: Hiroyuki surname: Asama fullname: Asama, Hiroyuki organization: Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan – sequence: 6 givenname: Yuki surname: Sato fullname: Sato, Yuki organization: Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan – sequence: 7 givenname: Hiroki surname: Irie fullname: Irie, Hiroki organization: Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan – sequence: 8 givenname: Yoshinori surname: Okubo fullname: Okubo, Yoshinori organization: Department of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan – sequence: 9 givenname: Jun surname: Nakamura fullname: Nakamura, Jun organization: Department of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan – sequence: 10 givenname: Mika surname: Takasumi fullname: Takasumi, Mika organization: Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan – sequence: 11 givenname: Minami surname: Hashimoto fullname: Hashimoto, Minami organization: Department of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan – sequence: 12 givenname: Tsunetaka surname: Kato fullname: Kato, Tsunetaka organization: Department of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan – sequence: 13 givenname: Ryoichiro surname: Kobashi fullname: Kobashi, Ryoichiro organization: Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan – sequence: 14 givenname: Takuto surname: Hikichi fullname: Hikichi, Takuto organization: Department of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan – sequence: 15 givenname: Hiromasa surname: Ohira fullname: Ohira, Hiromasa organization: Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34886831$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkltr3DAQhU1JaS7tH-hDMRRK--BUF-vil0AIvSykFHp5FrIsrxW8kivJofvvO5tN0nUpfrA8_uaMz_icFkc-eFsULzE6x1jy9wkTKVmFCK5Qg3hTNU-KE1wLXJEaiaOD83FxmtINQlhIJJ8Vx7SWkkuKT4r-i4thrVs9Ol_epnKK9uGpD7E0g92EPNiop23lfDcb25WTjW7a1cbS2zmGSedhW0LHpL2JVmdnSgNHG6GSnfU5PS-e9npM9sX9_az4-fHDj6vP1fXXT6ury-vK8KbOVaNJbzCnAvGWEdZhDuZwD2aFpJa1VGjBTMuo7BpiJeuxEZ0ggjNkNW4kPStWe90u6Bs1RbfRcauCduquEOJa6QjfN1rVI9oTCsNwTepWSs0ahnknutpwYVANWhd7rWluN7Yz4AMsL0SXb7wb1DrcKskZR5KAwNt7gRh-zTZltXHJ2HHU3oY5KQIUozC1AfT1P-hNmKOHVQGFMcW0qcVfaq3BgPN9gLlmJ6ouueQ1YQQxoM7_Q8HV2Y0zEKHeQX3R8G7RAEy2v_Nazymp1fdvS_bNATtYPeYhhXHOLvi0BMkeNDGkFG3_uDiM1C6-ah9fBX9Y3cVX7dbw6nDljy0PeaV_ANqY6Zc |
| CitedBy_id | crossref_primary_10_1136_bmjopen_2022_070645 crossref_primary_10_1186_s12885_023_11560_4 crossref_primary_10_56936_18290825_2022_16_4_89 crossref_primary_10_1097_j_pain_0000000000002852 crossref_primary_10_1167_iovs_64_5_27 crossref_primary_10_1523_ENEURO_0395_22_2022 crossref_primary_10_3390_jvd1010005 crossref_primary_10_1007_s00520_022_07317_7 crossref_primary_10_1136_spcare_2023_004362 crossref_primary_10_5387_fms_2021_32 crossref_primary_10_53469_jcmp_2024_06_06__40 |
| Cites_doi | 10.4103/jrms.JRMS_1068_17 10.1124/jpet.117.247551 10.1002/jso.23392 10.7150/jca.16279 10.3322/caac.21492 10.1007/s10147-015-0810-y 10.1186/s12885-017-3887-z 10.1634/theoncologist.2017-0066 10.1007/s10147-015-0784-9 10.5009/gnl18220 10.1038/ajg.2016.610 10.1200/JCO.2014.58.8533 10.1245/s10434-015-4647-4 10.1200/JCO.20.01399 10.1002/cncr.23008 10.1097/MPA.0b013e31829e2006 10.1186/1471-2407-12-199 10.1007/s00280-013-2102-4 10.1038/nrclinonc.2009.236 10.1248/bpb.b13-00735 10.1245/s10434-014-3898-9 10.1056/NEJMoa1011923 10.1248/bpb.32.732 10.1111/tbj.13196 10.1007/s10552-020-01303-2 10.21147/j.issn.1000-9604.2017.05.05 10.3109/0284186X.2015.1004367 10.1159/000329803 10.1007/s12094-015-1471-z 10.3892/etm.2011.375 10.1634/theoncologist.2017-0235 10.1200/JCO.2005.06.050 10.1007/s10147-010-0183-1 10.1055/s-0042-110793 10.1007/s00280-016-2972-3 10.1634/theoncologist.2012-0435 10.1038/bjc.2016.222 10.1007/s00280-013-2306-7 10.1586/era.12.115 10.3390/nu10040398 10.1007/s11596-012-1001-y 10.1111/jdi.13013 10.1200/JCO.2013.52.0536 10.1007/s10637-018-0598-5 10.7314/APJCP.2015.16.14.6001 10.21873/anticanres.11539 10.1002/cncr.27489 10.1097/j.pain.0000000000001577 10.3322/caac.21590 10.3892/ijo.2013.2176 10.1056/NEJMoa1304369 10.1177/1758834016676011 10.1053/j.seminoncol.2018.01.001 10.1007/s40261-019-00882-6 10.1200/JCO.2010.33.0308 10.1016/j.pain.2010.12.014 10.1523/JNEUROSCI.21-16-06095.2001 10.1007/s12032-012-0361-2 10.1007/s00520-015-2807-5 10.3390/cancers11040484 10.1093/jnci/dju413 10.1001/jama.2013.2813 10.1007/s10147-009-0015-3 10.1016/j.clcc.2014.09.005 10.1002/9780471420194.tnmc26.pub3 10.5603/GP.a2018.0034 10.1016/j.neuroscience.2006.09.044 |
| ContentType | Journal Article |
| Copyright | 2021. The Author(s). COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2021 |
| Copyright_xml | – notice: 2021. The Author(s). – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2021 |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12885-021-09069-9 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Gale In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE CrossRef Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2407 |
| EndPage | 1319 |
| ExternalDocumentID | oai_doaj_org_article_f03f231631424b88a59516d7d4c67c04 A686425205 10_1186_s12885_021_09069_9 34886831 |
| Genre | Journal Article |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GroupedDBID | --- -A0 0R~ 23N 2WC 3V. 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFGXO AFKRA AFNRJ AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EAD EAP EAS EBD EBS ECM EIF EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 M1P M48 M~E NPM O5R O5S OK1 P2P PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX ACMJI ALIPV CITATION EBLON PGMZT ABVAZ 7TO 7XB 8FK AZQEC DWQXO H94 K9. PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c694t-9a2fc163706b525d160211f186783e5b37a75cb538d92e85f1c7d727650ea1983 |
| IEDL.DBID | RPM |
| ISSN | 1471-2407 |
| IngestDate | Thu Jul 04 21:09:14 EDT 2024 Tue Sep 17 21:13:51 EDT 2024 Fri Aug 16 05:25:13 EDT 2024 Fri Sep 13 06:50:14 EDT 2024 Thu Feb 22 23:48:48 EST 2024 Fri Feb 02 04:27:27 EST 2024 Thu Aug 01 20:28:09 EDT 2024 Tue Aug 20 22:11:39 EDT 2024 Thu Sep 12 17:02:32 EDT 2024 Thu May 23 23:41:18 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | mirogabalin pregabalin pancreatic cancer chemotherapy-induced peripheral neuropathy |
| Language | English |
| License | 2021. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c694t-9a2fc163706b525d160211f186783e5b37a75cb538d92e85f1c7d727650ea1983 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656082/ |
| PMID | 34886831 |
| PQID | 2611313947 |
| PQPubID | 44074 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_f03f231631424b88a59516d7d4c67c04 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8656082 proquest_miscellaneous_2608539519 proquest_journals_2611313947 gale_infotracmisc_A686425205 gale_infotracacademiconefile_A686425205 gale_incontextgauss_ISR_A686425205 gale_healthsolutions_A686425205 crossref_primary_10_1186_s12885_021_09069_9 pubmed_primary_34886831 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-12-09 |
| PublicationDateYYYYMMDD | 2021-12-09 |
| PublicationDate_xml | – month: 12 year: 2021 text: 2021-12-09 day: 09 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC cancer |
| PublicationTitleAlternate | BMC Cancer |
| PublicationYear | 2021 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | EL Fogel (9069_CR6) 2017; 112 T Conroy (9069_CR8) 2011; 364 E Oki (9069_CR54) 2015; 20 L Marthey (9069_CR18) 2015; 22 EM Smith (9069_CR41) 2013; 309 BN Reeves (9069_CR39) 2012; 118 P Gauchan (9069_CR64) 2009; 32 PF Peddi (9069_CR10) 2012; 13 F Bray (9069_CR1) 2018; 68 J Kang (9069_CR34) 2018; 36 E Assaf (9069_CR9) 2011; 80 N Afshar (9069_CR3) 2020; 31 SJ Rombouts (9069_CR22) 2016; 7 M Baba (9069_CR44) 2019; 10 9069_CR46 KS Gunturu (9069_CR15) 2013; 30 R Xu (9069_CR33) 2017; 17 RD Rao (9069_CR60) 2007; 110 PJ Hosein (9069_CR11) 2012; 12 MN Zahir (9069_CR21) 2015; 16 T Kono (9069_CR53) 2013; 72 T Conroy (9069_CR7) 2005; 23 CL Loprinzi (9069_CR49) 2014; 32 E Salehifar (9069_CR43) 2020; 40 H Kaku (9069_CR52) 2012; 3 W Xiao (9069_CR63) 2007; 144 BA Boone (9069_CR36) 2013; 108 A Orlandi (9069_CR24) 2016; 18 A Stathis (9069_CR4) 2010; 7 DH Ahn (9069_CR30) 2017; 9 A Ottaiano (9069_CR37) 2017; 37 MS You (9069_CR35) 2018; 12 RL Siegel (9069_CR2) 2020; 70 DR Pachman (9069_CR40) 2015; 33 JE Faris (9069_CR14) 2013; 18 E Sadot (9069_CR20) 2015; 22 R Warsame (9069_CR5) 2012; 12 EA Mellon (9069_CR19) 2015; 54 AH Ko (9069_CR32) 2017; 22 A Boroujerdi (9069_CR67) 2011; 152 F Hohla (9069_CR16) 2014; 44 K Ishibashi (9069_CR48) 2010; 15 MK Chllamma (9069_CR23) 2016; 115 V Lorgis (9069_CR12) 2012; 32 E Wesselink (9069_CR50) 2018; 10 M Aoki (9069_CR66) 2014; 37 R Avan (9069_CR42) 2018; 23 M Magnowska (9069_CR61) 2018; 89 M Aghili (9069_CR62) 2019; 25 H Ueno (9069_CR29) 2016; 77 DS Zhang (9069_CR27) 2013; 71 M Nishioka (9069_CR51) 2011; 16 CL Loprinzi (9069_CR45) 2020; 38 A Hincker (9069_CR59) 2019; 160 S Pusceddu (9069_CR47) 2019; 11 9069_CR28 Y Hirayama (9069_CR55) 2015; 20 J Wang (9069_CR56) 2017; 29 DC de Andrade (9069_CR58) 2017; 22 P Peng (9069_CR65) 2012; 32 CL Loprinzi (9069_CR38) 2011; 29 SS Shinde (9069_CR57) 2016; 24 A Hann (9069_CR25) 2016; 54 SY Moorcraft (9069_CR17) 2014; 13 H Mahaseth (9069_CR13) 2013; 42 DD Von Hoff (9069_CR26) 2013; 369 IR Cho (9069_CR31) 2017; 44 J Barclay (9069_CR68) 2001; 21 Y Domon (9069_CR69) 2018; 365 |
| References_xml | – volume: 23 start-page: 52 year: 2018 ident: 9069_CR42 publication-title: J Res Med Sci. doi: 10.4103/jrms.JRMS_1068_17 contributor: fullname: R Avan – volume: 365 start-page: 573 year: 2018 ident: 9069_CR69 publication-title: J Pharmacol Exp Ther. doi: 10.1124/jpet.117.247551 contributor: fullname: Y Domon – volume: 108 start-page: 236 year: 2013 ident: 9069_CR36 publication-title: J Surg Oncol. doi: 10.1002/jso.23392 contributor: fullname: BA Boone – volume: 7 start-page: 1861 year: 2016 ident: 9069_CR22 publication-title: J Cancer. doi: 10.7150/jca.16279 contributor: fullname: SJ Rombouts – volume: 68 start-page: 394 year: 2018 ident: 9069_CR1 publication-title: CA Cancer J Clin. doi: 10.3322/caac.21492 contributor: fullname: F Bray – volume: 20 start-page: 866 year: 2015 ident: 9069_CR55 publication-title: Int J Clin Oncol. doi: 10.1007/s10147-015-0810-y contributor: fullname: Y Hirayama – volume: 17 start-page: 885 year: 2017 ident: 9069_CR33 publication-title: BMC Cancer. doi: 10.1186/s12885-017-3887-z contributor: fullname: R Xu – volume: 22 start-page: 1427 year: 2017 ident: 9069_CR32 publication-title: Oncologist. doi: 10.1634/theoncologist.2017-0066 contributor: fullname: AH Ko – volume: 20 start-page: 767 year: 2015 ident: 9069_CR54 publication-title: Int J Clin Oncol. doi: 10.1007/s10147-015-0784-9 contributor: fullname: E Oki – volume: 12 start-page: 728 year: 2018 ident: 9069_CR35 publication-title: Gut Liver. doi: 10.5009/gnl18220 contributor: fullname: MS You – volume: 112 start-page: 537 year: 2017 ident: 9069_CR6 publication-title: Am J Gastroenterol. doi: 10.1038/ajg.2016.610 contributor: fullname: EL Fogel – volume: 33 start-page: 3416 year: 2015 ident: 9069_CR40 publication-title: J Clin Oncol. doi: 10.1200/JCO.2014.58.8533 contributor: fullname: DR Pachman – volume: 22 start-page: 3512 year: 2015 ident: 9069_CR20 publication-title: Ann Surg Oncol. doi: 10.1245/s10434-015-4647-4 contributor: fullname: E Sadot – volume: 32 start-page: 4125 year: 2012 ident: 9069_CR12 publication-title: Anticancer Res. contributor: fullname: V Lorgis – volume: 38 start-page: 3325 year: 2020 ident: 9069_CR45 publication-title: J Clin Oncol. doi: 10.1200/JCO.20.01399 contributor: fullname: CL Loprinzi – volume: 110 start-page: 2110 year: 2007 ident: 9069_CR60 publication-title: Cancer. doi: 10.1002/cncr.23008 contributor: fullname: RD Rao – volume: 42 start-page: 1311 year: 2013 ident: 9069_CR13 publication-title: Pancreas. doi: 10.1097/MPA.0b013e31829e2006 contributor: fullname: H Mahaseth – volume: 12 start-page: 199 year: 2012 ident: 9069_CR11 publication-title: BMC Cancer. doi: 10.1186/1471-2407-12-199 contributor: fullname: PJ Hosein – volume: 71 start-page: 1065 year: 2013 ident: 9069_CR27 publication-title: Cancer Chemother Pharmacol. doi: 10.1007/s00280-013-2102-4 contributor: fullname: DS Zhang – volume: 7 start-page: 163 year: 2010 ident: 9069_CR4 publication-title: Nat Rev Clin Oncol. doi: 10.1038/nrclinonc.2009.236 contributor: fullname: A Stathis – volume: 37 start-page: 322 year: 2014 ident: 9069_CR66 publication-title: Biol Pharm Bull. doi: 10.1248/bpb.b13-00735 contributor: fullname: M Aoki – volume: 22 start-page: 295 year: 2015 ident: 9069_CR18 publication-title: Ann Surg Oncol. doi: 10.1245/s10434-014-3898-9 contributor: fullname: L Marthey – volume: 364 start-page: 1817 year: 2011 ident: 9069_CR8 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1011923 contributor: fullname: T Conroy – volume: 32 start-page: 732 year: 2009 ident: 9069_CR64 publication-title: Biol Pharm Bull. doi: 10.1248/bpb.32.732 contributor: fullname: P Gauchan – volume: 25 start-page: 226 year: 2019 ident: 9069_CR62 publication-title: Breast J. doi: 10.1111/tbj.13196 contributor: fullname: M Aghili – volume: 31 start-page: 617 year: 2020 ident: 9069_CR3 publication-title: Cancer Causes Control. doi: 10.1007/s10552-020-01303-2 contributor: fullname: N Afshar – volume: 29 start-page: 411 year: 2017 ident: 9069_CR56 publication-title: Chin J Cancer Res. doi: 10.21147/j.issn.1000-9604.2017.05.05 contributor: fullname: J Wang – volume: 54 start-page: 979 year: 2015 ident: 9069_CR19 publication-title: Acta Oncol. doi: 10.3109/0284186X.2015.1004367 contributor: fullname: EA Mellon – volume: 80 start-page: 301 year: 2011 ident: 9069_CR9 publication-title: Oncology. doi: 10.1159/000329803 contributor: fullname: E Assaf – volume: 18 start-page: 988 year: 2016 ident: 9069_CR24 publication-title: Clin Transl Oncol. doi: 10.1007/s12094-015-1471-z contributor: fullname: A Orlandi – volume: 3 start-page: 60 year: 2012 ident: 9069_CR52 publication-title: Exp Ther Med. doi: 10.3892/etm.2011.375 contributor: fullname: H Kaku – volume: 22 start-page: 1154 year: 2017 ident: 9069_CR58 publication-title: Oncologist. doi: 10.1634/theoncologist.2017-0235 contributor: fullname: DC de Andrade – volume: 23 start-page: 1228 year: 2005 ident: 9069_CR7 publication-title: J Clin Oncol. doi: 10.1200/JCO.2005.06.050 contributor: fullname: T Conroy – volume: 16 start-page: 322 year: 2011 ident: 9069_CR51 publication-title: Int J Clin Oncol. doi: 10.1007/s10147-010-0183-1 contributor: fullname: M Nishioka – volume: 54 start-page: 1138 year: 2016 ident: 9069_CR25 publication-title: Z Gastroenterol. doi: 10.1055/s-0042-110793 contributor: fullname: A Hann – volume: 77 start-page: 595 year: 2016 ident: 9069_CR29 publication-title: Cancer Chemother Pharmacol. doi: 10.1007/s00280-016-2972-3 contributor: fullname: H Ueno – volume: 18 start-page: 543 year: 2013 ident: 9069_CR14 publication-title: Oncologist. doi: 10.1634/theoncologist.2012-0435 contributor: fullname: JE Faris – volume: 115 start-page: 649 year: 2016 ident: 9069_CR23 publication-title: Br J Cancer. doi: 10.1038/bjc.2016.222 contributor: fullname: MK Chllamma – volume: 72 start-page: 1283 year: 2013 ident: 9069_CR53 publication-title: Cancer Chemother Pharmacol. doi: 10.1007/s00280-013-2306-7 contributor: fullname: T Kono – volume: 12 start-page: 1327 year: 2012 ident: 9069_CR5 publication-title: Expert Rev Anticancer Ther. doi: 10.1586/era.12.115 contributor: fullname: R Warsame – volume: 10 start-page: 398 year: 2018 ident: 9069_CR50 publication-title: Nutrients. doi: 10.3390/nu10040398 contributor: fullname: E Wesselink – volume: 32 start-page: 586 year: 2012 ident: 9069_CR65 publication-title: J Huazhong Univ Sci Technolog Med Sci. doi: 10.1007/s11596-012-1001-y contributor: fullname: P Peng – volume: 10 start-page: 1299 year: 2019 ident: 9069_CR44 publication-title: J Diabetes Investig. doi: 10.1111/jdi.13013 contributor: fullname: M Baba – volume: 32 start-page: 997 year: 2014 ident: 9069_CR49 publication-title: J Clin Oncol. doi: 10.1200/JCO.2013.52.0536 contributor: fullname: CL Loprinzi – volume: 36 start-page: 732 year: 2018 ident: 9069_CR34 publication-title: Invest New Drugs. doi: 10.1007/s10637-018-0598-5 contributor: fullname: J Kang – volume: 16 start-page: 6001 year: 2015 ident: 9069_CR21 publication-title: Asian Pac J Cancer Prev. doi: 10.7314/APJCP.2015.16.14.6001 contributor: fullname: MN Zahir – volume: 37 start-page: 1975 year: 2017 ident: 9069_CR37 publication-title: Anticancer Res. doi: 10.21873/anticanres.11539 contributor: fullname: A Ottaiano – volume: 118 start-page: 5171 year: 2012 ident: 9069_CR39 publication-title: Cancer. doi: 10.1002/cncr.27489 contributor: fullname: BN Reeves – volume: 160 start-page: 1835 year: 2019 ident: 9069_CR59 publication-title: Pain. doi: 10.1097/j.pain.0000000000001577 contributor: fullname: A Hincker – volume: 70 start-page: 7 year: 2020 ident: 9069_CR2 publication-title: CA Cancer J Clin. doi: 10.3322/caac.21590 contributor: fullname: RL Siegel – volume: 44 start-page: 319 year: 2014 ident: 9069_CR16 publication-title: Int J Oncol. doi: 10.3892/ijo.2013.2176 contributor: fullname: F Hohla – volume: 369 start-page: 1691 year: 2013 ident: 9069_CR26 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1304369 contributor: fullname: DD Von Hoff – volume: 9 start-page: 75 year: 2017 ident: 9069_CR30 publication-title: Ther Adv Med Oncol. doi: 10.1177/1758834016676011 contributor: fullname: DH Ahn – volume: 44 start-page: 420 year: 2017 ident: 9069_CR31 publication-title: Semin Oncol. doi: 10.1053/j.seminoncol.2018.01.001 contributor: fullname: IR Cho – volume: 40 start-page: 249 year: 2020 ident: 9069_CR43 publication-title: Clin Drug Investig. doi: 10.1007/s40261-019-00882-6 contributor: fullname: E Salehifar – volume: 29 start-page: 1472 year: 2011 ident: 9069_CR38 publication-title: J Clin Oncol. doi: 10.1200/JCO.2010.33.0308 contributor: fullname: CL Loprinzi – volume: 152 start-page: 649 year: 2011 ident: 9069_CR67 publication-title: Pain. doi: 10.1016/j.pain.2010.12.014 contributor: fullname: A Boroujerdi – volume: 21 start-page: 6095 year: 2001 ident: 9069_CR68 publication-title: J Neurosci. doi: 10.1523/JNEUROSCI.21-16-06095.2001 contributor: fullname: J Barclay – volume: 30 start-page: 361 year: 2013 ident: 9069_CR15 publication-title: Med Oncol. doi: 10.1007/s12032-012-0361-2 contributor: fullname: KS Gunturu – volume: 24 start-page: 547 year: 2016 ident: 9069_CR57 publication-title: Support Care Cancer. doi: 10.1007/s00520-015-2807-5 contributor: fullname: SS Shinde – volume: 11 start-page: 484 year: 2019 ident: 9069_CR47 publication-title: Cancers (Basel). doi: 10.3390/cancers11040484 contributor: fullname: S Pusceddu – ident: 9069_CR28 doi: 10.1093/jnci/dju413 – volume: 309 start-page: 1359 year: 2013 ident: 9069_CR41 publication-title: JAMA. doi: 10.1001/jama.2013.2813 contributor: fullname: EM Smith – volume: 15 start-page: 82 year: 2010 ident: 9069_CR48 publication-title: Int J Clin Oncol. doi: 10.1007/s10147-009-0015-3 contributor: fullname: K Ishibashi – volume: 13 start-page: 232 year: 2014 ident: 9069_CR17 publication-title: Clin Colorectal Cancer. doi: 10.1016/j.clcc.2014.09.005 contributor: fullname: SY Moorcraft – volume: 13 start-page: 497 year: 2012 ident: 9069_CR10 publication-title: JOP. contributor: fullname: PF Peddi – ident: 9069_CR46 doi: 10.1002/9780471420194.tnmc26.pub3 – volume: 89 start-page: 200 year: 2018 ident: 9069_CR61 publication-title: Ginekol Pol. doi: 10.5603/GP.a2018.0034 contributor: fullname: M Magnowska – volume: 144 start-page: 714 year: 2007 ident: 9069_CR63 publication-title: Neuroscience. doi: 10.1016/j.neuroscience.2006.09.044 contributor: fullname: W Xiao |
| SSID | ssj0017808 |
| Score | 2.4576385 |
| Snippet | The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin... Abstract Background The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin,... Background The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and... BACKGROUNDThe prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and... Abstract Background The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin,... |
| SourceID | doaj pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 1319 |
| SubjectTerms | 5-Fluorouracil Aged Analgesics - therapeutic use Anticonvulsants Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biopsy Bridged Bicyclo Compounds - therapeutic use Cancer Cancer therapies Chemotherapy chemotherapy-induced peripheral neuropathy Comparative analysis Complications and side effects Consent Drug dosages Drug therapy Drug-Related Side Effects and Adverse Reactions - drug therapy Female Fluorouracil - adverse effects Fluorouracil - therapeutic use Gemcitabine Humans Irinotecan Irinotecan - adverse effects Irinotecan - therapeutic use Leucovorin - adverse effects Leucovorin - therapeutic use Male Middle Aged mirogabalin Neurotoxicity Normal distribution Oxaliplatin Oxaliplatin - adverse effects Oxaliplatin - therapeutic use Paclitaxel Pancreatic cancer Pancreatic Neoplasms - complications Pancreatic Neoplasms - drug therapy Patients Peripheral nerve diseases Peripheral Nervous System Diseases - chemically induced Peripheral Nervous System Diseases - drug therapy Peripheral neuropathy pregabalin Pregabalin - therapeutic use Retrospective Studies Treatment Outcome Ultrasonic imaging |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gLAsojUIpBSBxQ1CSOX8dSURWk5QBU6s2yHbtUKtlqs4vUf89M4qzW4sClx8QTJZnxjL9JZj4T8j4E8GbZilJpyHRaHVxpYZ0rW9epylphW4kNzotv4uy8_XrBL3a2-sKasIkeeFLcUaxYBAwiGLZkOaUsB0wgOtm1XkifmEBrPidT6f-BVJWaW2SUOBogCivsRK7xu4TQpc6WoZGt_9-YvLMo5QWTOyvQ6SPyMEFHejw98mNyL_RPyP1F-jm-T-LiarW8tA6QdU__DPRmFeYjQKYUrPM7tVvdlpCJg007ijzHI7HANR2ZLXGD4lsKV0CQmPCkpx4nxoomBtbhKTk__fzz5KxM2yiUXuh2XWrbRA8KlJVwvOFdLUAPdUQmO8UCd0xayb2DyNfpJigeay87gDWA3YKttWLPyF6_7MMLQptYN12ElAl54CyzyoU28OAsDxEyk6YgH2etmpuJLcOMWYYSZrKBgXub0QZGF-QTKn4riUzX4wmwv0n2N_-zf0HeoNnM1Da69VdzLBSkVrypeEHejRLIdtFjOc2l3QyD-fLjeyb0IQnFJZjY29SdAO-NBFmZ5EEmCe7o8-F5_pgUDgYDaWrNAGu3siBvt8N4JZa49WG5QRlAvwxeDvTyfJpuW80wCLNCsbogMpuImerykf7q10gWrpBdSTUv70LXr8iDBn0Iq3n0AdlbrzbhNWCytTsc3e8vPcQxcA priority: 102 providerName: Directory of Open Access Journals – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9RAFB5qC-KLeDdaNYrgg4RNMtc8SSstq7BFqoW-DTOTyVrQZE12hf57z0kmsUHwcXdO2M25zXdm5nxDyFvvIZolE4kqoNJhhbeJgXkuYbZUqTHCMIkNzqszsbxgny_55R5Zjr0weKxyzIl9oi4bh2vkC0D6GQW4wuTCWFwFcNvFh82vBO-Pwn3WcJnGLXKQZww3bA-OT86-nE87ClKlamyaUWLRQV5W2Juc4UqFKJJiNjH1_P3_Zukb09T8COWNOen0HrkbwGR8NFj_Ptnz9QNyexW2yx-SanXVNmtjAWvX8e8u3rR-_ARYNQZ7_QwNWNcJ1OZg5TJG5uOeauBH3HNd4pXF1zE8AWljQJgudugqbRw4WbtH5OL05NvHZRIuVkicKNg2KUxeOQBiMhWW57zMBOghq5DbTlHPLZVGcmchF5ZF7hWvMidLADqA5rzJCkUfk_26qf1TEudVlpcVFFHIDGeoUdYzz7013FdQq-QReT9qVW8G_gzd1x1K6MEGGn5b9zbQRUSOUfGTJHJf91807VqHUNJVSitApYJik55VynBAiaKUJXNCupRF5BWaTQ-NpFME6yOhoNjiecoj8qaXQP6LGg_YrM2u6_Snr-czoXdBqGrQ3UzoV4D3RsqsmeThTBIC1M2HR__RIUF0-q87R-T1NIxP4qG32jc7lAE8TOHlQC9PBnebNEMh8QpFs4jImSPOVDcfqa--9_ThCvmWVP7s_3_rObmTY3TgyZ3ikOxv251_Afhra1-G0PoD_yIvcA priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZKkRAXxJuUAgYhcUChG79zQKggqoK0HICVerOcxF4qlaRNdhH775lxkqURvXDceJJV5uVvYs9nQl56D9GshUpNDpWOyH2ROpjnUlFUZuacckJjg_P8izpeiM8n8mSHjMcdDQrsrizt8DypRXv25vfF5h0E_NsY8EYddJBjDfYZZ_jVQeVpfo1cZ4IL9Pi5-LuqoE08oS6DhIyrCnpsornyGZOJKvL5_5u1L01b0y2Vl-aoo9vk1gAu6WHvDXfIjq_vkhvzYfn8Hgnz07ZZugKwd01_dfS89eMvwK4U7PdzaMjapFCrg9UrikzIkXrgjEbuSzzCeEPhDkgjPeIsaYmu09KBo7W7TxZHH79_OE6HgxbSUuVileaOhRKAmZ6pQjJZZQr0kAXkujPcy4Jrp2VZQG6scuaNDFmpKwA-gO68y3LDH5Dduqn9I0JZyFgVoKhCpjjHnSm88NIXTvoAtQtLyOtRq_a859OwsQ4xyvY2sPDfNtrA5gl5j4rfSiIXdrzQtEs7hJYNMx4ApSqOTXuFMU4CalSVrkSpdDkTCXmGZrN9Y-k2ou2hMlB8STaTCXkRJZAPo8YNN0u37jr76dvXidCrQSg0YOLSDf0L8N5IoTWR3J9IQsCW0-HRf-zo7xYK2YwDGhc6Ic-3w3gnboKrfbNGGcDHHF4O9PKwd7etZjgkYmV4lhA9ccSJ6qYj9emPSCdukH_JsL3_ssxjcpNhsODGnnyf7K7atX8C8GxVPI0x9wfPdDNM priority: 102 providerName: Scholars Portal |
| Title | Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34886831 https://www.proquest.com/docview/2611313947/abstract/ https://search.proquest.com/docview/2608539519 https://pubmed.ncbi.nlm.nih.gov/PMC8656082 https://doaj.org/article/f03f231631424b88a59516d7d4c67c04 |
| Volume | 21 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZtB2MvY_d66zJvDPYw3NjW1Y9NaekGKSVbIexFSLKcBRo7xMmg_35Hshxq9rYXQ6wjHJ-L9B37nM8IfbYWopkTlogCMh1SWJ0o2OcSokuRKsUU4a7BeXrNrm7J9zmdHyDa98L4on2jl6f13eq0Xv72tZXrlRn3dWLjm-m5cIwxIh8fokOOcZ-ih1cHXKSi744RbNzCAixcE3LmHkmwInE8oRjclgmcDTYjz9n_78r8YGsalk0-2Icun6GnAUDGZ90ffY4ObP0CPZ6GV-QvUTVdbpqF0oCv6_hPG683tv8F-DQGG61C09V9Avk4WLaMHduxpxe4iz2_pftM8X0MM2Cp6FCliY1zj00ceFjbV-j28uLn-VUSPqaQGFaQbVKovDIAvnjKNM1pmTFQSVY5PjuBLdWYK06NhvWvLHIraJUZXgK4AQRnVVYI_Bod1U1tj1GcV1leVpA4OTY4hZXQllhqtaK2gvwkj9DXXqty3XFmSJ9rCCY7c0i4tvTmkEWEJk7xe0nHd-1PNJuFDFaXVYorQKIMu8Y8LYSigAxZyUtiGDcpidAHZzbZNY_uo1aeMQEJFs1TGqFPXsJxXtSuqGahdm0rv_2YDYS-BKGqARMbFXoU4L4dTdZA8mQgCUFphsO9_8iwKLQSktUMA-ImPEIf98Nupit0q22zczKAgTHcHOjlTedue830XhshPnDEgeqGIxBBnjI8RMzb_575Dj3JXQy5Qp7iBB1tNzv7HuDYVo8gCOd8hB5NLq5vZiP_UAOOUyLgOJv8Gvnw_AsE1jjB |
| link.rule.ids | 230,315,733,786,790,870,891,2115,12083,21416,24346,27957,27958,31754,31755,33779,33780,43345,43840,53827,53829 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSMCl4llSCg0IiQOKmsTPnFBBVFvo9gCttDfLceylEiRLsovUf89M4iyNkDhuPFE2M57xN87MZ0LeOAfeLJlIVAGZDitcmRhY5xJWVio1RhgmscF5fi5ml-zzgi_ChlsXyirHmNgH6qqxuEd-BEg_owBXmHy_-pXgqVH4dTUcoXGb3GGUMizpk4ttwpVJlaqxUUaJow5iscJ-5Ax3J0SRFJPFqOfs_zcy31iapmWTN9ahkwdkNwDI-Hiw-ENyy9WPyN15-ET-mPj5VdssTQn4uo5_d_GqdeMvwKcx2OhnaLq6TiAfB8tWMbId9_QCP-Ke3xKPKb6O4Q4IFQOqtLHF6dHGgYe1e0IuTz5dfJwl4TCFxIqCrZPC5N4C-JKpKHnOq0yAHjKPfHaKOl5SaSS3JcS_qsid4j6zsgJwAwjOmaxQ9CnZqZvaPSNx7rO88pA4IRucoUaVjjnuSsOdh_wkj8i7Uat6NXBm6D7XUEIPNtDwbN3bQBcR-YCK30oi33V_oWmXOriP9in1gEQFxca8UinDARmKSlbMCmlTFpFDNJsemke3XquPhYIEi-cpj8jrXgI5L2osqlmaTdfp029fJ0Jvg5BvwMTWhB4FeG-kyZpIHkwkwSntdHicPzoEhU7_ncIRebUdxjux0K12zQZlAANTeDnQy94w3baaoRBshaJZRORkIk5UNx2pr773lOEKOZZUvv__v3VI7s0u5mf67PT8y3NyP0dPwcqd4oDsrNuNewH4a12-7J3sD_yfLT0 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgSBMv3C8ZgwWExANKm5sveRyDagM6TcCkiRfLduxSbU2rpkUav55znKRq4G2PqY8V2f6O_Z3mnM-EvLUWvJnnLBIFRDp5YXWk4JyLcl2KWCmmco4FzuNTdnyef76gF1tXffmkfaOng-pqNqimv3xu5WJmhl2e2PBsfCRQMUakw0XphrfJHfDZtOgC9fYDAhex6GpkBBvWsA0LLEVO8I8JVkSoFpoBeJnIkt6R5JX7_9-ftw6ofvLk1mk0uk9-duNoklAuB-uVHpg__0g83migD8i9lqOGh43JQ3LLVo_I7rj9Cv-YuPF0OZ8oDRS-Cn_X4WJpuyegwCHAYNbWdV1HEPIDeMoQBZW9gsFV6CU08Sbk6xB6wG7UEFcTGkTgMmylXusn5Hz06cfRcdTe1xAZVuSrqFCpM8DveMw0TWmZMJjvxKFknsgs1RlXnBoNy1UWqRXUJYaXwJ-AJFqVFCJ7SnaqeWWfkzB1SVo6iM1QcE5lSmibW2q1otZBCJQG5H23ZHLRyHJIH84IJpu1lvBu6ddaFgH5gKu6sURJbf_DfDmR7XxLF2cOyC7LsPZPC6EokE9W8jI3jJs4D8gBYkI29ambjUEeMgExHE1jGpA33gJlNSrM25modV3Lk-_fekbvWiM3B_wY1ZZBwLhRiatnud-zBL83_eYOnLLdd2oJ8XCSAanPeUBeb5qxJ-bSVXa-Rhug2RkMDublWYPlzcx0LhEQ3kN5b-r6LYBdr0reYnXvxj0PyO7Zx5H8enL65QW5m6KvYtpQsU92Vsu1fQnkb6VfeTf_C_CvV90 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mirogabalin+vs+pregabalin+for+chemotherapy-induced+peripheral+neuropathy+in+pancreatic+cancer+patients&rft.jtitle=BMC+cancer&rft.au=Sugimoto%2C+Mitsuru&rft.au=Takagi%2C+Tadayuki&rft.au=Suzuki%2C+Rei&rft.au=Konno%2C+Naoki&rft.date=2021-12-09&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=21&rft.issue=1&rft_id=info:doi/10.1186%2Fs12885-021-09069-9&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12885_021_09069_9 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |